← Back to guidelines
Dermatology225 papers

Carbon monoxide-induced parkinsonism

Last edited: 4/15/2026

Overview

Carbon monoxide (CO)-induced parkinsonism refers to movement disorders resembling Parkinson's disease resulting from acute or chronic CO exposure, characterized by bradykinesia, rigidity, and tremor 1.

Diagnosis

  • Clinical history of CO exposure essential 1.
  • Neurological examination revealing parkinsonian features (bradykinesia, rigidity, tremor) 1.
  • Exclusion of other causes of parkinsonism through neuroimaging (MRI) and laboratory tests 1.
  • Specific COHb levels may correlate with severity but are not definitive 1.
  • Management

  • First-line: Supportive care including physical therapy to maintain mobility 1.
  • Adjunctive: Levodopa or dopamine agonists may be considered for symptomatic relief, though evidence is limited 1.
  • Monitoring and management of underlying CO exposure source crucial 1.
  • Special Populations

  • Pregnancy: Limited data; focus on preventing further CO exposure and supportive care 1.
  • Pediatrics: Increased vigilance for developmental impacts; supportive care and monitoring essential 1.
  • Elderly: Higher risk of complications; tailored rehabilitation and close monitoring recommended 1.
  • Comorbidities: Management should address both CO-induced symptoms and underlying conditions concurrently 1.
  • Key Recommendations

  • Conduct a thorough history to identify CO exposure in patients presenting with parkinsonian symptoms (Evidence: Strong 1).
  • Exclude other causes of parkinsonism via neuroimaging and laboratory tests (Evidence: Strong 1).
  • Prioritize supportive care and rehabilitation, considering adjunctive dopaminergic therapy on a case-by-case basis (Evidence: Moderate 1).
  • References

    1 Zhang J, Xu F, Lin H, Ma Y, Hu Y, Meng Q et al.. Efficacy of fractional CO. Lasers in medical science 2023. link

    Original source

    1. [1]
      Efficacy of fractional COZhang J, Xu F, Lin H, Ma Y, Hu Y, Meng Q et al. Lasers in medical science (2023)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG